773071-56-0

Basic information

• Product Name: methyl 2-(3,4-dimethoxybenzamido)thiophene-3-carboxylate
• Synonyms: methyl 2-(3,4-dimethoxybenzamido)thiophene-3-carboxylate
• CAS NO: 773071-56-0
• Molecular Weight: 321.354
• Mol File: 773071-56-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 2-(3,4-dimethoxybenzamido)thiophene-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(3,4-dimethoxybenzamido)thiophene-3-carboxylate(773071-56-0)
• EPA Substance Registry System: methyl 2-(3,4-dimethoxybenzamido)thiophene-3-carboxylate(773071-56-0)

Safety Data

• Hazardous Substances Data: 773071-56-0(Hazardous Substances Data)

Upstream product

• 93-07-2 Veratric acid 
• 4651-81-4 Methyl 2-aminothiophene-3-carboxylate 
• 3535-37-3 3,4-dimethoxybenzoic acid chloride 

Downstream Products

• 773071-57-1 2-(3,4-dimethoxy-benzoylamino)-5-formylthiophene-3-carboxylic acid methyl ester 

Relevant articles and documents

Synthesis, biological evaluation and molecular docking studies of novel trimethoxy-ring derivatives as BRD4 inhibitors

Background: Bromodomain-containing protein 4 (BRD4) inhibitors synthesized with trimethoxy-ring refer to a new series of small molecular inhibitors. Currently, BRD4 offers the potential for research as a cancer therapeutic target. Based on previous studies, 17 trimethoxy-ring derivatives were designed as novel BRD4 inhibitors. Methods: All these new compounds were synthesized via the amide reaction. Their structures were identified by 1H NRM,13C NRM spectra and HRMS. In vitro antitumor activities of the new compounds were evaluated by MTT. Molecular docking studies were conducted to explain the binding interactions of these compounds with BRD4 protein. Results: A series of novel trimethoxy-ring derivatives were synthesized as BRD4 inhibitors and screened by testing their inhibition against HCT116, MCF-7, K562 and KMS-1 cell lines. Most of the newly synthesized compounds exhibited moderate-to-good inhibitory activity against HCT116, MCF-7, and K562 cell lines, whereas some showed inhibitory activity against the KMS-1 cell line. Conclusion: Compound 3g demonstrated the most potent anti-tumor activity against breast (MCF-7), leukemia (K562), multiple myeloma (KMS-1), and colon cancer (HCT116) cell lines.

COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME

An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and ---- represents a single bond or a double bond, R5 represents optionally substituted aryl or the like, Z represents - N=CHR6R7 or the like, R6 and R7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R101 and R102 together form =O, and R103 and R104 represent H, or R101 and R104 together from a bond, and R102 and R103 together form a bond.